Neimeth International Pharmaceuticals Plc Reports 9% Earnings Growth Amid Rising Costs

Neimeth International Pharmaceuticals Plc has seen a 9% year-on-year increase in profit after tax to N339.77 million for the nine months ending September 2025. The company's revenue surged by 62% to N5.01 billion, driven by increased product demand and better market penetration.

However, the company faced challenges such as a steep increase in financial costs, impacting its operating margin. Neimeth's gross profit also saw a significant increase to N2.49 billion.

Despite these challenges, the company's total assets grew by 11.3% to N13.35 billion. Neimeth continues to navigate Nigeria's challenging pharmaceutical environment amidst inflationary pressures and exchange rate volatility.